|Bid||197.67 x 900|
|Ask||200.25 x 1000|
|Day's Range||200.28 - 203.71|
|52 Week Range||141.41 - 249.27|
|Beta (5Y Monthly)||0.66|
|PE Ratio (TTM)||48.28|
|Earnings Date||Feb. 15, 2022|
|Forward Dividend & Yield||1.30 (0.65%)|
|Ex-Dividend Date||Jan. 19, 2022|
|1y Target Est||248.83|
Let's look at two excellent companies that could turn $250,000 into $1,000,000 -- that's a compound annual growth rate of 14.87% -- in the next 10 years: Zoetis (NYSE: ZTS) and Spotify (NYSE: SPOT). Zoetis is one of the leading animal health companies in the world. Zoetis boasts 13 products that generate $100 million or more in annual revenue, and its financial results continue to impress.
PARSIPPANY, N.J., January 13, 2022--Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved Solensia™ to control the pain of osteoarthritis (OA) in cats.
The U.S. health regulator on Thursday approved Zoetis Inc's once-a-month injection to treat pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints in older cats. Osteoarthritis breaks down the protective cartilage that cushions the joints, leading to increased friction that causes pain and decreased movement. The drug, Solensia, with the active ingredient frunevetmab, is the first veterinary monoclonal antibody approved by the U.S. Food and Drug Administration.